PE20231855A1 - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas - Google Patents

Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas

Info

Publication number
PE20231855A1
PE20231855A1 PE2023001605A PE2023001605A PE20231855A1 PE 20231855 A1 PE20231855 A1 PE 20231855A1 PE 2023001605 A PE2023001605 A PE 2023001605A PE 2023001605 A PE2023001605 A PE 2023001605A PE 20231855 A1 PE20231855 A1 PE 20231855A1
Authority
PE
Peru
Prior art keywords
alkyl
optionally substituted
factor receptor
cyclopentathiophen
receptor antagonists
Prior art date
Application number
PE2023001605A
Other languages
English (en)
Spanish (es)
Inventor
Matthias Eckhardt
Marina Kristina Willwacher
Juergen Prestle
Ferenc Kontes
Christofer Tautermann
Dieter Wiedenmayer
Leo Thomas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20231855A1 publication Critical patent/PE20231855A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2023001605A 2020-11-16 2021-11-12 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas PE20231855A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207719 2020-11-16
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Publications (1)

Publication Number Publication Date
PE20231855A1 true PE20231855A1 (es) 2023-11-21

Family

ID=73543025

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001605A PE20231855A1 (es) 2020-11-16 2021-11-12 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas

Country Status (19)

Country Link
US (2) US11766443B2 (https=)
EP (1) EP4244229A1 (https=)
JP (2) JP7465368B2 (https=)
KR (1) KR20230109692A (https=)
CN (2) CN116745300A (https=)
AR (1) AR124070A1 (https=)
AU (1) AU2021379248A1 (https=)
CA (1) CA3200710A1 (https=)
CL (2) CL2023001361A1 (https=)
CO (1) CO2023005894A2 (https=)
CR (1) CR20230211A (https=)
DO (1) DOP2023000090A (https=)
EC (1) ECSP23036210A (https=)
IL (1) IL302769A (https=)
JO (1) JOP20230107A1 (https=)
MX (1) MX2023005678A (https=)
PE (1) PE20231855A1 (https=)
SA (1) SA523440809B1 (https=)
WO (1) WO2022101377A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
IE870123L (en) * 1986-01-21 1987-07-21 Boehringer Ingelheim Int Thieno-1,4-diazepines
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
CA2670031A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
CN117624188A (zh) 2024-03-01
CR20230211A (es) 2023-07-13
CN116745300A (zh) 2023-09-12
US20220160725A1 (en) 2022-05-26
WO2022101377A1 (en) 2022-05-19
US20230355638A1 (en) 2023-11-09
CO2023005894A2 (es) 2023-05-29
ECSP23036210A (es) 2023-06-30
AR124070A1 (es) 2023-02-08
JP2024099528A (ja) 2024-07-25
KR20230109692A (ko) 2023-07-20
TW202237620A (zh) 2022-10-01
JP7465368B2 (ja) 2024-04-10
MX2023005678A (es) 2023-05-26
US11766443B2 (en) 2023-09-26
JP7810743B2 (ja) 2026-02-03
CA3200710A1 (en) 2022-05-19
AU2021379248A9 (en) 2024-10-10
CL2024000317A1 (es) 2024-07-12
DOP2023000090A (es) 2023-06-15
JOP20230107A1 (ar) 2023-05-16
AU2021379248A1 (en) 2023-06-22
IL302769A (en) 2023-07-01
CL2023001361A1 (es) 2023-11-03
SA523440809B1 (ar) 2024-10-08
JP2023521200A (ja) 2023-05-23
EP4244229A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20221336A1 (es) Compuestos triciclicos sustituidos
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
PE20210856A1 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
PE20081346A1 (es) Derivados de espiroindolinona como antagonistas de mdm2
PE20081454A1 (es) Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor
ECSP056097A (es) Antagonistas del receptor cgrp
PE20040805A1 (es) Indazolilpirrolotriazinas c-6 modificadas
AR114810A1 (es) Procesos e intermedios para elaborar un inhibidor de jak
PE20090718A1 (es) Derivados de espiroindolinona
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
PE20121471A1 (es) Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
CO2022011388A2 (es) Inhibidores heterocíclicos de pad4
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
MX2023010317A (es) Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica
ECSP055572A (es) Derivados ciclotiocarbamativos como moduladores pr y el uso de los mismos en el tratamiento de enfermedades de la piel.
PE20231855A1 (es) Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas
PE20080399A1 (es) Derivados de alquilpiridazina
DOP2011000326A (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)- bencensulfonamida o bencensulfonil-fenil-(pipezina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
CL2023001301A1 (es) 1,4-diazepanonas bicíclicas y sus usos terapéuticos.